A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Subjects With Stage III/IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Subjects With Stage III/IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL
  • Sponsors Gradalis
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 24 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Feb 2017 Planned number of patients changed from 574 to 222.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top